Physician profile
Charles E Kerr
NPI 1568495406
$3,606.00
in general payments reported to CMS, 2019-2025
29 companies · $1,269 in 2025
The $1,269 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $473 · 2020: $112 · 2022: $11.71 · 2023: $435 · 2024: $1,305 · 2025: $1,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,896 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,895.93 |
| Education | $113.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $498.51 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $464.79 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.98 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $373.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $271.77 | 2019-2025 | Gardasil 9, Capvaxive, Verquvo |
| Abbvie INC. | $211.74 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $152.91 | 2023-2025 | |
| Astellas Pharma US INC | $130.11 | 2019-2025 | Veozah |
| Amgen INC. | $118.31 | 2019-2025 | Repatha, Otezla, Prolia |
| Novartis Pharmaceuticals Corporation | $114.04 | 2019-2024 | |
| Exact Sciences Corporation | $108.10 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $105.27 | 2019-2024 | Spravato |
| Glaxosmithkline, LLC. | $102.63 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $98.70 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $91.68 | 2023-2025 | Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $51.88 | 2024 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $50.91 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.97 | 2025 | Caplyta |
| Abbott Laboratories | $40.14 | 2024-2025 | Freestyle Libre 3 |
| Viatris Specialty LLC | $32.68 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $27.97 | 2024-2025 | Eliquis |
| Mylan Specialty L.P. | $25.00 | 2024 | Yupelri |
| Hikma Pharmaceuticals USA | $20.50 | 2023 | Mitigare, Ryaltris |
| Phathom Pharmaceuticals, INC. | $18.25 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $15.59 | 2025 | Zenpep |
| Esperion Therapeutics, INC. | $15.19 | 2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $12.57 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.92 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Kerr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.